• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Disc Medicine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/7/25 8:05:23 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IRON alert in real time by email
    8-K
    0001816736false00018167362025-05-072025-05-07

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 07, 2025

     

     

    DISC MEDICINE, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-39438

    85-1612845

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    321 Arsenal Street

    Suite 101

     

     

    Watertown, Massachusetts

     

    02472

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 617 674-9274

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    IRON

     

    The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 7, 2025, Disc Medicine, Inc. announced its financial results for the first quarter ended March 31, 2025 and provided a corporate update. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

    The following exhibit relating to Item 2.02 of this Current Report on Form 8-K shall be deemed to be furnished and not filed:

     

    Exhibit No.

     

    Description

    99.1

     

    Press release issued by Disc Medicine, Inc. on May 7, 2025, furnished herewith.

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    DISC MEDICINE, INC.

     

     

     

     

    Date:

    May 7, 2025

    By:

    /s/ John Quisel, J.D., Ph.D.

     

     

     

    Name: John Quisel, J.D., Ph.D.
    Title: Chief Executive Officer

     


    Get the next $IRON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IRON

    DatePrice TargetRatingAnalyst
    2/27/2025Buy
    TD Cowen
    11/5/2024$85.00Equal-Weight → Overweight
    Morgan Stanley
    11/4/2024$66.00 → $110.00Outperform → Strong Buy
    Raymond James
    10/23/2024$89.00Buy
    Jefferies
    10/16/2024Sector Outperform
    Scotiabank
    8/22/2024$75.00Overweight
    Wells Fargo
    4/1/2024$40.00Strong Buy → Outperform
    Raymond James
    12/19/2023$56.00 → $65.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $IRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Savage William Jacob sold $105,367 worth of shares (2,100 units at $50.17), decreasing direct ownership by 3% to 66,398 units (SEC Form 4)

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      5/6/25 8:53:25 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Quisel John D exercised 7,000 shares at a strike of $1.01, increasing direct ownership by 5% to 161,828 units (SEC Form 4)

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      4/8/25 8:22:20 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ashiya Mona sold $310,483 worth of shares (5,738 units at $54.11) (SEC Form 4)

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      3/26/25 7:08:01 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    Leadership Updates

    Live Leadership Updates

    See more
    • Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

      Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed study parameters with the potential for accelerated approval based on existing dataPresented proof-of-mechanism data for Phase 1b trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia at the American Society of Nephrology (ASN) Kidney Week 2024Eight posters and an oral presentation across all three clinical-stage assets to be presented at the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionStrong financial position ending Q3 with $487 million in cash, cash equivalents, and m

      11/12/24 8:00:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer

      WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Rahul Rajan Kaushik, Ph.D. as the company's Chief Technical Officer. Dr. Kaushik is an experienced biotech executive with significant expertise in chemistry, manufacturing, and controls (CMC) leadership across technical development, manufacturing and supply chain oversight for products in multiple modalities and therapeutic areas. "Rahul's experience is an ideal fit for Disc as we evolve in

      10/23/24 8:00:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

      WATERTOWN, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Steve Caffé, MD as the company's Chief Regulatory Officer. Dr. Caffé is an experienced biotech executive with significant expertise in global regulatory leadership across a wide range of therapeutic areas, including hematology, oncology, and rare diseases. "We are excited to welcome an executive as accomplished as Steve to Disc, where his depth of regulatory expertise and experience in glo

      9/19/24 8:30:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update

      Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with EPPPlan to initiate Phase 2 study of DISC-3405 in polycythemia vera (PV) in H1 2025Expect data readouts for DISC-0974 program in H2 2025, including initial results of Phase 2 anemia of myelofibrosis (MF) study and multiple dose data from Phase 1b anemia of non-dialysis dependent chronic kidney disease (NDD-CKD) studyStrong financial position supported by $259 million public offering in January 2025; ended Q1 with $695 million in cash, cash equivalents, and marketable securities, which is expected to

      5/7/25 8:00:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF)

      WATERTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it will host a virtual KOL investor event on Friday, May 9 at 1:00 PM ET / 10:00 AM PT to provide an overview of anemia of myelofibrosis (MF) and discuss the evolving treatment landscape for this disease. The event will also include an overview of Disc's clinical data and development plans for DISC-0974 in MF anemia. Intended for investors and other interested audiences, the virtual event will feature presen

      4/29/25 8:00:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Targeting NDA submission for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 through accelerated approval pathway; on track to initiate APOLLO post-marketing confirmatory trial by mid-2025Positive update from Phase 1b trial of DISC-0974 in patients with anemia of myelofibrosis (MF) presented at ASH 2024; initial data from ongoing Phase 2 expected in H2 2025Positive data from initial cohorts of ongoing Phase 1b study of DISC-0974 in patients with anemia of non-dialysis-dependent chronic kidney disease (NDD-CKD) presented at ASN Kidney Week 2024; initial data from multiple dose portion of this study expected in H2 2025Presented first-in-human SAD/MAD data from Phase 1 trial of DIS

      2/27/25 8:00:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

      SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

      11/14/24 5:44:55 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

      SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

      11/14/24 4:33:10 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Disc Medicine Inc.

      SC 13G - Disc Medicine, Inc. (0001816736) (Subject)

      11/8/24 10:52:39 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    SEC Filings

    See more
    • SEC Form 10-Q filed by Disc Medicine Inc.

      10-Q - Disc Medicine, Inc. (0001816736) (Filer)

      5/7/25 8:37:27 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Disc Medicine, Inc. (0001816736) (Filer)

      5/7/25 8:05:23 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Disc Medicine Inc.

      DEFA14A - Disc Medicine, Inc. (0001816736) (Filer)

      4/24/25 4:47:32 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    Financials

    Live finance-specific insights

    See more
    • Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

      Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on existing clinical data, including results from BEACON and AURORA Phase 2 trialsAchieved regulatory alignment on APOLLO post-marketing confirmatory trial design and on track to initiate trial by mid-year 2025Aligned on average monthly time in light without pain during the last month of the 6-month treatment period and percent change from baseline in whole-blood metal-free PPIX after 6 months of treatment as coprimary endpoints for confirmatory trialManagement will host a conference call on Tuesday, Ja

      1/21/25 7:45:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

      WATERTOWN, Mass., Jan. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its Type C meeting on bitopertin in EPP with the U.S. Food and Drug Administration (FDA). The conference call will be held on Tuesday, January 21, at 8:00 am EST. Conference Call Information Please register for the event on the Events and Presentations page of Disc's website at https://ir.discmedicine.com/. About Bitopertin Bitopertin is an investigationa

      1/20/25 7:00:00 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

       Positive updates across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in existing and additional indicationsManagement hosted a conference call during the ASH meeting on Sunday, December 8 discussing highlights of the presented data and next steps for the company WATERTOWN, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today spotlights 8 posters presented at the ASH 2024 annual meeting in San Diego, C

      12/9/24 12:00:00 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Disc Medicine

      TD Cowen initiated coverage of Disc Medicine with a rating of Buy

      2/27/25 6:22:05 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Disc Medicine from Equal-Weight to Overweight and set a new price target of $85.00

      11/5/24 7:18:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine upgraded by Raymond James with a new price target

      Raymond James upgraded Disc Medicine from Outperform to Strong Buy and set a new price target of $110.00 from $66.00 previously

      11/4/24 9:40:15 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bitterman Kevin bought $8,000,028 worth of shares (222,223 units at $36.00) (SEC Form 4)

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      6/20/24 8:00:05 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ashiya Mona bought $3,000,024 worth of shares (83,334 units at $36.00) (SEC Form 4)

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      6/20/24 5:27:54 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Orbimed Advisors Llc bought $3,000,024 worth of shares (83,334 units at $36.00) (SEC Form 4)

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      6/20/24 5:19:39 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care